Pranay Randad joined Flagship as an Associate after completing the Flagship Pioneering Fellowship in 2020. At Flagship, Pranay works as part of a team of entrepreneurial scientists to conceive, create, resource, and develop first-in-category biotech ventures.
Pranay completed his doctoral and postdoctoral training at Johns Hopkins Bloomberg School of Public Health, where he combined interdisciplinary skills in epidemiology, molecular biology and biotechnology to drive impact across a breadth of infectious disease and public health issues. Leveraging advanced epidemiological and molecular methods, his doctoral research pioneered approaches that revealed transmission of antimicrobial resistant bacteria between factory farm pigs and people in the top pig-producing regions in the U.S. During the COVID-19 pandemic, Pranay was part of a team that developed and patented a salivary SARS-CoV-2 antibody test that is now used for immunosurveillance and antibody testing by local governments and academic institutions. While completing his graduate studies, Pranay helped design and implement a vaccine trial in rural Bangladesh, in partnership with Sanofi Pasteur, to study vaccine response and cross-placental antibody transfer among pregnant woman and their newborns. He is the recipient of multiple awards from Johns Hopkins University, the National Institute of Occupational Safety & Health, and various philanthropic organizations.
Prior to graduate school, Pranay worked at QIAGEN on advanced molecular diagnostics for cancer. He earned a B.S. in Physiology and Neurobiology from University of Maryland, College Park and an M.S. in Biochemistry & Molecular Biology from Georgetown University.